AstraZeneca strikes up to $1.5 billion AI drug discovery deal with Insitro

The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...
Independent Journal Review

AstraZeneca signs $1.5 billion AI drug-discovery deal

AstraZeneca has partnered with AI biotech insitro to identify drug targets and develop potential treatments for MASH, a ...

AstraZeneca strikes $40 million AI drug discovery deal with Insitro

By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...
Crypto Briefing

AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion

AstraZeneca partners with insitro on an AI drug discovery deal worth up to $1.86 billion targeting fatty liver disease and ...

Ministry of Science signs MoU with Peptris for collab in AI-based drug discovery and development

TDB will provide Rs 86 crore to Peptris Technologies for a Rs 172-crore project to advance four AI-discovered experimental ...
Stock Titan

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Holbrook most recently led cardiovascular, renal and hepatic disease and in vitro discovery platforms at Novo Nordisk; she ...

We cannot just look at drug discovery. Japan's precarious pharmaceutical industry

Domestic active pharmaceutical ingredients (APIs) are an endangered species. Can generic manufacturers struggling with drug ...

Appearing as an "AI-driven drug discovery startup," it was actually building an infrastructure to deliver "shelved drugs" to patients with rare diseases — Dissecting …

I first learned about GexVal when it was featured as an AI drug discovery startup on TV Tokyo's "World Business Satellite ...

AstraZeneca Signs AI Drug-Discovery Deal Worth Up to $1.5 Billion. Only $40 Million Is Guaranteed

AstraZeneca (AZN) signed a drug-discovery deal with AI biotech insitro on Thursday, October 15, aimed at MASH, a serious liver disease, and cardiomyopathies, a group of heart-muscle diseases. The ...

Artificial Intelligence (AI) in Drug Discovery Market - Global Strategic Insights and Forecast, 2026-2031 | 31.7% CAGR Drives a USD 3.97 Billion Opportunity by 2031

Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- "Artificial Intelligence in Drug Discovery Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The ...

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically ...
BioSpace

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...